Dr. Janjigian Discusses MSI Testing in Gastric Cancer

Yelena Y. Janjigian, MD
Published: Tuesday, Sep 19, 2017



Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 


Yelena Y. Janjigian, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses testing for microsatellite instability (MSI) testing in patients with gastric cancer.

Though MSI-high is a relatively rare subset of gastric cancer, it is very important to distinguish these patients, says Janjigian.

MSI status must be routinely tested, Janjigian adds, because even if patients do not meet MSI criteria, a higher mutational burden may increase their chances of responding to therapy.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Emerging Treatment Options for Patients With High-Risk AMLMay 31, 20181.0
Oncology Briefings™: Updates in Pediatric Hepatic Veno-Occlusive Disease: Integrating Novel Therapeutic Strategies to Overcome Post-Transplant ObstaclesMay 31, 20181.0
Publication Bottom Border
Border Publication
x